ClinicalTrials.gg
CompletedNCT00296816TEACOUpdated Aug 23, 2012Results posted

TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary

A Phase 2 interventional study of Bevacizumab (Avastin®) and Docetaxel (Taxotere®) in Ovarian Cancer, sponsored by Sanofi. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-08-23.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
132
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 106 studies testing bevacizumab in Ovarian Neoplasms — 22 open to participants now, 32 under way, 9 of them phase 3. Bevacizumab · Ovarian Neoplasms.

Enrollment
28th of 106
132 · median 52
Started
2006
with 5 others
Phase 2
66 of 106
11 open now
Registered
8th of 106
by date

Among the 106 studies testing bevacizumab in Ovarian Neoplasms, this one is the 28th largest by enrollment, is one of 6 that started in 2006, is one of 66 in phase 2, and was the 8th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

22 of the 106 studies testing bevacizumab in Ovarian Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies testing bevacizumab in Ovarian Neoplasms, or all of them as a file.
02

Study summary

Feasibility study to assess a novel combination of cytotoxic agents, docetaxel and oxaliplatin, as first-line therapy in the treatment of ovarian cancer and the impact of angiogenesis inhibition for the progression and prognosis of ovarian cancer by concurrent addition of bevacizumab (Avastin®).

Read the detailed description

Participants were

  • administered study medication approximately 28 days after initial surgery for ovarian cancer
  • received the study treatment regimen of up to one year unless there was disease progression, unacceptable toxicity, death, participant refusal, or treatment delay beyond the time frame permitted for each treatment

Participants were followed for survival for a minimum 3 years from the date of enrollment

03

Conditions studied

  • Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Females 18 years of age or older
  2. Participants with a histologic diagnosis of ovarian, primary peritoneal, or fallopian tube carcinoma, Stage Ib- IV, with either optimal (≤ 1 cm residual disease) or suboptimal residual disease ( > 1 cm maximal diameter any remaining lesion) following initial surgery.
  3. Participants with the following histologic epithelial cell types are eligible: Serious adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma,undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell carcinoma, malignant Brenner's Tumor, or adenocarcinoma N.O.S.
  4. Participant must have adequate bone marrow function
  5. Participant must have adequate renal function
  6. Participant must have adequate urine protein/creatinine reaction (UPC) of \<1.0;
  7. Participant must have adequate neurologic function
  8. Hepatic function: Total ≤ ; and ALT and Alkaline Phosphatase must be within the range allowing for eligibility. In determining eligibility the more abnormal of the two values (AST or ALT) should be used.
  9. Blood Coagulation parameters: PT such that (INR) is \< 1.5 (or an in-range INR, usually between 2 and 3, if a participant is on stable dose of therapeutic Warfarin or low molecular weight heparin) and a PTT \< 1.2 times the upper limit normal.
  10. Participants must be enrolled in the study prior to 50 days (every effort will be made for prior to 28 days) after initial surgery performed for the combined purpose of diagnosis, staging and cytoreduction.
  11. Participants with measurable and non- are eligible. Participants with suboptimal disease are eligible. Participants may or may not have cancer-related symptoms.
  12. Participants who have met the pre-entry requirements specified including serologic measurement of CA-125 as a baseline for subsequent determination of response using Rustin criteria.
  13. Participants with a GOG Performance Status of 0, 1, or 2.

Exclusion criteria

EXCLUSION CRITERIA:

  1. Participants with a current diagnosis of epithelial ovarian tumor of low malignant potential (Borderline carcinomas) are not eligible. Participants with a prior diagnosis of a low malignant potential tumor that was surgically resected and who subsequently develop invasive adenocarcinoma are eligible, provided that they have not received prior chemotherapy for any ovarian tumor.
  2. Germ cell tumors, sex cord-stromal tumors, carcinosarcomas, mixed mullerian tumors or carcinosarcomas, carcinomas from other sites to the ovary and low malignant potential tumors including so called micropapillary serous carcinomas are not eligible.
  3. Participants who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded. Prior radiation for localized cancer of the skin is permitted, provided that it was completed more than 5 years prior to enrollment, and the participant remains free of recurrent or metastatic disease.
  4. Participants who have received any prior anticancer chemotherapy or biologic therapy for any are excluded.
  5. Participants with synchronous primary endometrial cancer, or a past history of primary endometrial cancer, are excluded, unless all of the following conditions are met: Stage not greater than I-B; Less than 3 mm invasion without vascular or lymphatic invasion; No poorly differentiated subtypes, including papillary serous, clear cell, or other FIGO Grade 3 lesions.
  6. Participants with any history of cancer, with the exception of inclusion criteria #2 and #3, and non-melanoma skin cancer, who are cancer free for the last 5 years, are excluded.
  7. Participant with acute hepatitis or active infection that requires parenteral antibiotics.
  8. Participants with serious, non-healing wound, ulcer, or bone fracture. This includes history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 28 days.

    Participants with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require weekly wound examinations.

  9. Participants with active bleeding or pathologic conditions that carry high risk of bleeding,such as known bleeding disorder, coagulopathy, or tumor involving major vessels.
  10. Participants with history or evidence upon physical examination of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any , or history of cerebrovascular accident (CVA, stroke), (TIA) or subarachnoid hemorrhage within six months of the first date of treatment on this study.
  11. Participants with cardiovascular disease.
  12. Participants with clinically significant proteinuria. Urine protein should be screened by urinalysis. Participants discovered to have a urine protein: serum creatinine ratio greater than or equal to 1 should undergo a 24-hour urine collection, which must be an adequate collection and must demonstrate \< 1000 mg protein/24 hr to allow participation in the study.
  13. Participants with or with anticipation of invasive procedures.
  14. Participants with GOG Performance Grade of 3 or 4.
  15. Participants who are pregnant or nursing.
  16. Participants with known to Chinese hamster ovary cell products or other recombinant human or humanized antibodies and hypersensitivity to polysorbate 80 or hypersensitivity to any of the study drugs and its ingredients.
  17. Participants who participated in a study with any product/device within the last 30 days.
  18. Any medical condition that in the judgment of the investigator would jeopardize any participant safety or the study drug evaluation for efficacy and safety.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
132 participants (actual)

Study arms

  • Experimental
    Oxaliplatin/Docetaxel/Bevacizumab

    Participants with International Federation of Gynecology and Obstetrics (FIGO) stage IB through IV ovarian, primary peritoneal, or fallopian tube carcinoma treated with Oxaliplatin, Docetaxel, and Bevacizumab - 28 days after initial surgery

    Drug: Bevacizumab (Avastin®) · Drug: Docetaxel (Taxotere®) · Drug: Oxaliplatin (Eloxatin®)

Interventions

  • 15 mg/kg bevacizumab administered intravenously (IV) over 30 to 90 minutes on Day 1 of every 3 week cycle for 12 months or until disease progression or unacceptable toxicity

  • 75 mg/m\^2 docetaxel was administered IV over 1 hour on Day 1 of every 3 week cycle for 6 cycles or until disease progression or unacceptable toxicity

  • 85 mg/m\^2 Oxaliplatin was administered IV over 2 hours on Day 1 of every 3 week cycle for 6 cycles or until disease progression or unacceptable toxicity

06

What researchers measure

Primary outcomes

  1. Twelve-month Progression-free Survival (PFS) Rate in Participants

    Tumor assessments were performed by Computed tomography (CT) and Magnetic Resonance Imaging (MRI) to evaluate disease progression based on Gynecologic Oncology Group (GOG) Response Evaluation Criteria in Solid Tumors (RECIST). Disease progression was recorded as any one of the following: * appearance of a new lesion * symptomatic deterioration * progression of target or nontarget lesions * death Participants who did not die or show show disease progression achieved PFS. PFS rate is the percent of participants who achieved PFS.

    Time frame: up to 12 months following treatment initiation

Secondary outcomes

  1. Twenty Four-month Progression-free Survival (PFS) Rate in Participants

    Tumor assessments were performed by Computed tomography (CT) and Magnetic Resonance Imaging (MRI) to evaluate disease progression based on Gynecologic Oncology Group (GOG) Response Evaluation Criteria in Solid Tumors (RECIST). Disease progression was recorded as any one of the following: * appearance of a new lesion * symptomatic deterioration * progression of target or nontarget lesions * death Participants who did not die or show show disease progression achieved PFS. PFS rate is the percent of participants who achieved PFS.

    Time frame: up to 24 months following treatment initiation

  2. Median Time to Progression-free Survival (PFS)

    Time to PFS was the interval from the date of registration to the earliest date of disease progression or death, whichever occurred first. Time of PFS was censored * on the last available tumor assessment date for participants leaving the study prior to disease progression or death; and also for participants requiring off-study medication or additional debulking surgery (where assessment date used was the one prior to off-study medication or surgery), * at Day 1, for living participants with no post-baseline tumor assessments. Median PFS was estimated from a Kaplan-Meier curve.

    Time frame: up to approximately 1300 days following treatment initiation

  3. Tumor Response Rate Based on Gynecologic Oncology Group (GOG) Response Evaluation Criteria in Solid Tumors (RECIST)

    Tumors were assessed by CT and MRI. Tumor response was evaluated by GOG RECIST in which: * Complete response (CR) was the disappearance of all target and non-target lesions, with no evidence of new lesions * Partial response (PR) was at least a 30% decrease in the sum of longest dimensions (LD) of all measurable target lesions Participants with a response (CR or PR) were to have the initial response confirmed by tumor imaging in 4-6 weeks.

    Time frame: up to 12 months following treatment initiation

  4. Twelve-month Recurrence-free Survival (RFS) Rate in Participants With Non Measurable Disease at Baseline

    Participants with Recurrence-free survival (RFS) were participants with a non-measurable disease at baseline, who had not achieved disease progression nor had died. Disease progression included the following: * the appearance of a new lesion * symptomatic deterioration * progression of non-target lesions * a predefined serum CA 125 increase. RFS rate was the percent of participants in the non-measurable disease subgroup who achieved RFS.

    Time frame: up to 12 months following treatment initiation

  5. Median Time to Recurrence-free Survival (RFS) in Participants With Non-measurable Disease at Baseline

    The time to RFS was programmatically defined as the interval from the date of registration to the earliest date of disease progression or death, whichever occurred first. Participants were * censored on the last available CA 125 biomarker blood draw date if * left the study prior to disease progression or death * they received off-study anti-tumor medication * underwent debulking surgery * censored at Day 1 if they were alive had no post baseline CA 125 biomarker blood draw.

    Time frame: up to approximately 1500 days following treatment initiation

  6. CA-125 Response Rate

    A CA-125 response was considered at least a 50% reduction in the level of the biomarker, CA-125, from a pretreatment level, which was confirmed and maintained for at least 28 days. The overall CA-125 biomarker response rate was defined as the number of participants in the measurable disease subgroup who met the above criteria at least once within the study treatment period +21 days, divided by the number of evaluable participants in the disease subgroup.

    Time frame: up to 12 months after treatment initiation

  7. Overall Survival Rate

    Survival was the observed length of life from entry into the study to death or the date of last contact. The overall survival rate (percentage of participants showing survival) at 12 and 24-months is reported here.

    Time frame: up to up to approximately 1700 days after treatment initiation

  8. Median Overall Survival Time

    Survival was the observed length of life from entry into the study to death or the date of last contact. The median overall survival time was estimated using Kaplan-Meier Curve.

    Time frame: up to approximately 1700 days after treatment initiation

07

Results

Posted Aug 23, 2012
Limitations and caveats
One site closed prematurely during the study. Every effort was made to collect, at minimum, any outstanding safety data for the participants at this site. As a result, participants from this site were included only in the safety analysis.

Participant flow

152 participants were screened for the study. 20 were screen failures. 132 participants met eligibity criteria and were treated with study medication.

Participant flow — Overall Study
MilestoneOxaliplatin/Docetaxel/Bevacizumab
Started132
Completed58
Not completed74
Withdrew: Disease progression37
Withdrew: Adverse event18
Withdrew: Investigator/participant request5
Withdrew: Non-compliance1
Withdrew: Missing for end of treatment4
Withdrew: Progression based on ca-125 (biomarker)2
Withdrew: Poor performance status1
Withdrew: Relocation to florida1
Withdrew: Noncompliance/decision to discontinue1
Withdrew: Urine protein/creatinine ratio delay1
Withdrew: Neuropathy/patient preference1
Withdrew: Proteinuria1
Withdrew: Ineligibility due to radiation treatment1

Outcome measures

PrimaryTwelve-month Progression-free Survival (PFS) Rate in Participants

Tumor assessments were performed by Computed tomography (CT) and Magnetic Resonance Imaging (MRI) to evaluate disease progression based on Gynecologic Oncology Group (GOG) Response Evaluation Criteria in Solid Tumors (RECIST). Disease progression was recorded as any one of the following: * appearance of a new lesion * symptomatic deterioration * progression of target or nontarget lesions * death Participants who did not die or show show disease progression achieved PFS. PFS rate is the percent of participants who achieved PFS.

Time frame:
up to 12 months following treatment initiation
Reported as:
Number · percentage of participants
Twelve-month Progression-free Survival (PFS) Rate in Participants
percentage of participantsOxaliplatin/Docetaxel/Bevacizumab
Twelve-month Progression-free Survival (PFS) Rate in Participants65.7 (53.4 to 76.7)
SecondaryTwenty Four-month Progression-free Survival (PFS) Rate in Participants

Tumor assessments were performed by Computed tomography (CT) and Magnetic Resonance Imaging (MRI) to evaluate disease progression based on Gynecologic Oncology Group (GOG) Response Evaluation Criteria in Solid Tumors (RECIST). Disease progression was recorded as any one of the following: * appearance of a new lesion * symptomatic deterioration * progression of target or nontarget lesions * death Participants who did not die or show show disease progression achieved PFS. PFS rate is the percent of participants who achieved PFS.

Time frame:
up to 24 months following treatment initiation
Reported as:
Number · percentage of participants
Twenty Four-month Progression-free Survival (PFS) Rate in Participants
percentage of participantsOxaliplatin/Docetaxel/Bevacizumab
Twenty Four-month Progression-free Survival (PFS) Rate in Participants34.3 (23.3 to 46.6)
SecondaryMedian Time to Progression-free Survival (PFS)

Time to PFS was the interval from the date of registration to the earliest date of disease progression or death, whichever occurred first. Time of PFS was censored * on the last available tumor assessment date for participants leaving the study prior to disease progression or death; and also for participants requiring off-study medication or additional debulking surgery (where assessment date used was the one prior to off-study medication or surgery), * at Day 1, for living participants with no post-baseline tumor assessments. Median PFS was estimated from a Kaplan-Meier curve.

Time frame:
up to approximately 1300 days following treatment initiation
Reported as:
Median · days
Median Time to Progression-free Survival (PFS)
daysOxaliplatin/Docetaxel/Bevacizumab
Median Time to Progression-free Survival (PFS)495 (384 to 596)
SecondaryTumor Response Rate Based on Gynecologic Oncology Group (GOG) Response Evaluation Criteria in Solid Tumors (RECIST)

Tumors were assessed by CT and MRI. Tumor response was evaluated by GOG RECIST in which: * Complete response (CR) was the disappearance of all target and non-target lesions, with no evidence of new lesions * Partial response (PR) was at least a 30% decrease in the sum of longest dimensions (LD) of all measurable target lesions Participants with a response (CR or PR) were to have the initial response confirmed by tumor imaging in 4-6 weeks.

Time frame:
up to 12 months following treatment initiation
Reported as:
Number · participants
Tumor Response Rate Based on Gynecologic Oncology Group (GOG) Response Evaluation Criteria in Solid Tumors (RECIST)
participantsOxaliplatin/Docetaxel/Bevacizumab
Unconfirmed response (CR+PR)51
Unconfirmed complete response (CR)23
Unconfirmed partial response (PR)28
Unconfirmed progressive disease (PD)5
Confirmed response (CR+PR)41
Confirmed complete response (CR)21
Confirmed partial response (PR)20
SecondaryTwelve-month Recurrence-free Survival (RFS) Rate in Participants With Non Measurable Disease at Baseline

Participants with Recurrence-free survival (RFS) were participants with a non-measurable disease at baseline, who had not achieved disease progression nor had died. Disease progression included the following: * the appearance of a new lesion * symptomatic deterioration * progression of non-target lesions * a predefined serum CA 125 increase. RFS rate was the percent of participants in the non-measurable disease subgroup who achieved RFS.

Time frame:
up to 12 months following treatment initiation
Reported as:
Number · percentage of participants
Twelve-month Recurrence-free Survival (RFS) Rate in Participants With Non Measurable Disease at Baseline
percentage of participantsOxaliplatin/Docetaxel/Bevacizumab
Twelve-month Recurrence-free Survival (RFS) Rate in Participants With Non Measurable Disease at Baseline67.5 (50.9 to 81.4)
SecondaryMedian Time to Recurrence-free Survival (RFS) in Participants With Non-measurable Disease at Baseline

The time to RFS was programmatically defined as the interval from the date of registration to the earliest date of disease progression or death, whichever occurred first. Participants were * censored on the last available CA 125 biomarker blood draw date if * left the study prior to disease progression or death * they received off-study anti-tumor medication * underwent debulking surgery * censored at Day 1 if they were alive had no post baseline CA 125 biomarker blood draw.

Time frame:
up to approximately 1500 days following treatment initiation
Reported as:
Median · days
Median Time to Recurrence-free Survival (RFS) in Participants With Non-measurable Disease at Baseline
daysOxaliplatin/Docetaxel/Bevacizumab
Median Time to Recurrence-free Survival (RFS) in Participants With Non-measurable Disease at Baseline631 (427 to NA)
SecondaryCA-125 Response Rate

A CA-125 response was considered at least a 50% reduction in the level of the biomarker, CA-125, from a pretreatment level, which was confirmed and maintained for at least 28 days. The overall CA-125 biomarker response rate was defined as the number of participants in the measurable disease subgroup who met the above criteria at least once within the study treatment period +21 days, divided by the number of evaluable participants in the disease subgroup.

Time frame:
up to 12 months after treatment initiation
Reported as:
Number · percentage of participants
CA-125 Response Rate
percentage of participantsOxaliplatin/Docetaxel/Bevacizumab
With non-measurable disease at baseline (N=27)81.5 (61.9 to 93.7)
With measurable disease at baseline (N=53)83.0 (70.2 to 91.9)
SecondaryOverall Survival Rate

Survival was the observed length of life from entry into the study to death or the date of last contact. The overall survival rate (percentage of participants showing survival) at 12 and 24-months is reported here.

Time frame:
up to up to approximately 1700 days after treatment initiation
Reported as:
Number · percentage of participants
Overall Survival Rate
percentage of participantsOxaliplatin/Docetaxel/Bevacizumab
Overall survival at 12 months85.5 (77.5 to 91.5)
Overall survival at 24 months71.8 (62.4 to 80.0)
SecondaryMedian Overall Survival Time

Survival was the observed length of life from entry into the study to death or the date of last contact. The median overall survival time was estimated using Kaplan-Meier Curve.

Time frame:
up to approximately 1700 days after treatment initiation
Reported as:
Median · days
Median Overall Survival Time
daysOxaliplatin/Docetaxel/Bevacizumab
Median Overall Survival Time1437.0 (1036.0 to NA)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oxaliplatin/Docetaxel/Bevacizumab—33/132 (25%)130/132 (98.5%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventOxaliplatin/Docetaxel/Bevacizumab
NauseaGastrointestinal disorders7/132
VomitingGastrointestinal disorders7/132
Small intestinal obstructionGastrointestinal disorders5/132
Pulmonary embolismRespiratory, thoracic and mediastinal disorders5/132
Febrile neutropeniaBlood and lymphatic system disorders4/132
Abdominal painGastrointestinal disorders3/132
DehydrationMetabolism and nutrition disorders3/132
NeutropeniaBlood and lymphatic system disorders1/132
Cardiac failure congestiveCardiac disorders1/132
Supraventricular tachycardiaCardiac disorders1/132
Most frequent other events
Showing 10 of 79
Most frequent other events
EventOxaliplatin/Docetaxel/Bevacizumab
FatigueGeneral disorders101/132
AlopeciaSkin and subcutaneous tissue disorders86/132
NauseaGastrointestinal disorders85/132
DiarrhoeaGastrointestinal disorders77/132
Neuropathy peripheralNervous system disorders64/132
NeutropeniaBlood and lymphatic system disorders59/132
ConstipationGastrointestinal disorders59/132
ArthralgiaMusculoskeletal and connective tissue disorders47/132
Decreased appetiteMetabolism and nutrition disorders44/132
VomitingGastrointestinal disorders42/132

Baseline characteristics

Age Continuous
Age Continuous(years)Oxaliplatin/Docetaxel/Bevacizumab (Measurable Disease)Oxaliplatin/Docetaxel/Bevacizumab (Non-Measurable Disease)Total
Mean57.5 ± 10.4360.9 ± 9.5458.8 ± 10.19
Sex: Female, Male
Sex: Female, Male(Participants)Oxaliplatin/Docetaxel/Bevacizumab (Measurable Disease)Oxaliplatin/Docetaxel/Bevacizumab (Non-Measurable Disease)Total
Female8052132
Male000
Primary Tumor Site
Primary Tumor Site(participants)Oxaliplatin/Docetaxel/Bevacizumab (Measurable Disease)Oxaliplatin/Docetaxel/Bevacizumab (Non-Measurable Disease)Total
Ovary6545110
Fallopian tube6511
Peritoneum9211
FIGO stage at diagnosis
FIGO stage at diagnosis(participants)Oxaliplatin/Docetaxel/Bevacizumab (Measurable Disease)Oxaliplatin/Docetaxel/Bevacizumab (Non-Measurable Disease)Total
Stage IB000
Stage IC033
Stage IIA000
Stage IIB000
Stage IIC358
Stage IIIA325
Stage IIIB257
Stage IIIC573289
Stage IV15520
08

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2006, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2006
First posted
Feb 27, 2006
Start
Mar 2006
Primary completionActual
Aug 2011
CompletionActual
Aug 2011
Results first posted
Aug 23, 2012
Last update
Aug 23, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00296816
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Feb 27, 2006
Start date
Mar 2006
Primary completion
Aug 2011
Completion
Aug 2011
Results posted
Aug 23, 2012
Last update
Aug 23, 2012

Study contacts

Phyllis Diener, BS, MT (ASCP)
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Docetaxel · Oxaliplatin

Start the discussion